Syncona Limited - Achilles reports Q3 2023 Financial Results
Syncona Limited
Achilles reports Q3 2023 Financial Results and Recent Highlights
Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, notes that its portfolio company, Achilles Therapeutics Plc (Nasdaq: ACHL) ("Achilles"), announced its financial results for the second quarter ended
Key highlights included:
· On track to dose 15-20 patients at the higher dose level with its clonal neoantigen reactive T cells (cNeT) therapy by the end of 2023
· Updated clinical and translational science data from the Phase I/IIa trials in non small cell lung cancer (NSCLC) and melanoma will now be published in Q1 CY2024, with additional data available in mid-CY2024
· Strong cash position of
The announcement can be accessed on Achilles' website at: https://ir.achillestx.com/ and the full text of the announcement from Achilles is contained below.
[ENDS]
Enquiries
Syncona Ltd
Tel: +44 (0) 20 3981 7940
FTI Consulting
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
- On track to dose 15-20 patients with higher dose cNeT by year-end 2023 -
- Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 -
- Strong cash position of $140 million supports operations through 2025 -
London, UK
"We are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology. We believe that our proprietary capability to identify the most immunogenic clonal neoantigens, recently shared at ESGCT and SITC, puts us in a strong position with our clonal neoantigen-reactive T cell (cNeT) therapy and potentially other neoantigen targeting approaches," said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics. "Our Phase I/IIa clinical trials evaluating cNeT therapy for the treatment of advanced NSCLC (CHIRON) and metastatic malignant melanoma (THETIS) continue to progress and we are on track to dose patients in line with our previous guidance. We look forward to sharing our next clinical and translational data update in Q1 2024."
Recent Highlights
· Presented posters (Abstract 437, Abstract 1312) at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting highlighting a significant dose boost of reactive CD8 and CD4 cNeT from the optimized VELOSTM manufacturing platform and the use of the PELEUS™ AI-powered bioinformatics platform for the identification and validation of immunogenic clonal tumor neoantigens.
· Presented posters (P459, P485, P507) at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress highlighting the favorable cNeT phenotypic properties and polyfunctionality critical for precision adoptive cell therapies and the expansion of cNeT from the blood of patients with cancer.
· Delivered an oral presentation at the mRNA Cancer Vaccines Summit highlighting neoRanker™, a new AI-based tool for the selection of immunogenic clonal tumor neoantigens for personalized therapies.
· Delivered oral presentations at the 5th Annual TIL Therapies Summit highlighting optimized manufacturing of AI-powered precision TIL therapies for solid cancer, and the potency and fitness of cNeT.
· Presented posters (P319, P407, P518) at the Seventh International Cancer Immunotherapy Conference (CICON23) highlighting a precision adoptive cell therapy process based on expansion of cNeT from blood of cancer patients.
Financial Highlights
· Cash and cash equivalents: Cash and cash equivalents were
· Research and development (R&D) expenses: R&D expenses were
· General and administrative (G&A) expenses: G&A expenses were
· Net loss: Net loss for the third quarter ended
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward Looking Statements
This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing of the Company's clinical and translational data updates and the Company's beliefs about recent data updates, and expectations related to the Company's operating expenses and capital expense requirements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
For further information, please contact:
Investors:
Meru Advisors
Lee M. Stern
Media:
ICR Consilium
Sukaina Virji, Tracy Cheung, Emmalee Hoppe
+44 (0) 203 709 5000
achillestx@consilium-comms.com
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
|
|
|
|
|
|
|
|
||
|
|
|
2023 |
|
|
2022 |
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
140,138 |
|
|
$ |
173,338 |
|
|
Prepaid expenses and other current assets |
|
|
15,354 |
|
|
|
23,242 |
|
|
Total current assets |
|
|
155,492 |
|
|
|
196,580 |
|
|
Non-current assets: |
|
|
|
|
|
|
||
|
Property and equipment, net |
|
|
9,648 |
|
|
|
12,399 |
|
|
Operating lease right of use assets |
|
|
7,013 |
|
|
|
8,081 |
|
|
Deferred tax assets |
|
|
185 |
|
|
|
251 |
|
|
Restricted cash |
|
|
33 |
|
|
|
33 |
|
|
Other assets |
|
|
2,967 |
|
|
|
3,014 |
|
|
Total non-current assets |
|
|
19,846 |
|
|
|
23,778 |
|
|
TOTAL ASSETS |
|
$ |
175,338 |
|
|
$ |
220,358 |
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
5,352 |
|
|
$ |
5,187 |
|
|
Income taxes payable |
|
|
- |
|
|
|
326 |
|
|
Accrued expenses and other liabilities |
|
|
8,209 |
|
|
|
8,292 |
|
|
Operating lease liabilities-current |
|
|
4,620 |
|
|
|
4,188 |
|
|
Total current liabilities |
|
|
18,181 |
|
|
|
17,993 |
|
|
Non-current liabilities: |
|
|
|
|
|
|
||
|
Operating lease liabilities-non-current |
|
|
2,731 |
|
|
|
4,388 |
|
|
Other long-term liability |
|
|
941 |
|
|
|
933 |
|
|
Total non-current liabilities |
|
|
3,672 |
|
|
|
5,321 |
|
|
Total liabilities |
|
|
21,853 |
|
|
|
23,314 |
|
|
Commitments and contingencies (Note 12) |
|
|
|
|
|
|
||
|
Shareholders' equity: |
|
|
|
|
|
|
||
|
Ordinary shares, |
|
|
54 |
|
|
|
54 |
|
|
Deferred shares, |
|
|
128 |
|
|
|
128 |
|
|
Additional paid in capital |
|
|
413,815 |
|
|
|
408,844 |
|
|
Accumulated other comprehensive loss |
|
|
(19,190 |
) |
|
|
(21,695 |
) |
|
Accumulated deficit |
|
|
(241,322 |
) |
|
|
(190,287 |
) |
|
Total shareholders' equity |
|
|
153,485 |
|
|
|
197,044 |
|
|
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
|
$ |
175,338 |
|
|
$ |
220,358 |
|
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Research and development |
|
$ |
14,712 |
|
|
$ |
10,597 |
|
|
$ |
42,354 |
|
|
$ |
38,387 |
|
|
General and administrative |
|
|
4,384 |
|
|
|
5,437 |
|
|
|
13,387 |
|
|
|
17,162 |
|
|
Total operating expenses |
|
|
19,096 |
|
|
|
16,034 |
|
|
|
55,741 |
|
|
|
55,549 |
|
|
Loss from operations |
|
|
(19,096 |
) |
|
|
(16,034 |
) |
|
|
(55,741 |
) |
|
|
(55,549 |
) |
|
OTHER INCOME, NET: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other income |
|
|
2,389 |
|
|
|
3,599 |
|
|
|
4,692 |
|
|
|
8,499 |
|
|
Total other income, net |
|
|
2,389 |
|
|
|
3,599 |
|
|
|
4,692 |
|
|
|
8,499 |
|
|
Loss before provision for income taxes |
|
|
(16,707 |
) |
|
|
(12,435 |
) |
|
|
(51,049 |
) |
|
|
(47,050 |
) |
|
Benefit (Provision) for income taxes |
|
|
24 |
|
|
|
(41 |
) |
|
|
14 |
|
|
|
(70 |
) |
|
Net loss |
|
|
(16,683 |
) |
|
|
(12,476 |
) |
|
|
(51,035 |
) |
|
|
(47,120 |
) |
|
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Foreign exchange translation adjustment |
|
|
(5,289 |
) |
|
|
(18,147 |
) |
|
|
2,505 |
|
|
|
(45,126 |
) |
|
Comprehensive loss |
|
$ |
(21,972 |
) |
|
$ |
(30,623 |
) |
|
$ |
(48,530 |
) |
|
$ |
(92,246 |
) |
|
Net loss per share attributable to ordinary shareholders-basic and diluted |
|
$ |
(0.42 |
) |
|
$ |
(0.32 |
) |
|
$ |
(1.28 |
) |
|
$ |
(1.20 |
) |
|
Weighted average ordinary shares outstanding-basic and diluted |
|
|
40,066,922 |
|
|
|
39,313,764 |
|
|
|
39,900,910 |
|
|
|
39,104,866 |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE